Clinical trials: Hypertrophic Cardiomyopathy
Hypertrophic Obstructive Cardiomyopathy
The Safety and Influencing Factors of Liwen Procedure in The Treatment of Hypertrophic Cardiomyopathy
Liwen procedure is generally safe and effective in treating hypertrophic cardiomyopathy, but a small proportion of patients have complications after the operation.
- Trial name
- NCT06003478
- Testing
- Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy (Liwen Procedure)
- Where
- China
- Volunteers
- 486 people
- Sponsor
- Xijing Hospital
Coronary Cicrovascular Dysfunction, Hypertrophic Cardiomyopathy Patients
Prognostic Significance of CMD Assessed by IMR in HCM Patients
The index of microcirculatory resistance (IMR) serves as an indicator of coronary microvascular dysfunction (CMD) with significant prognostic value in various clinical conditions.
- Trial name
- caIMR-HCM (NCT06190704)
- Testing
- caIMR
- Volunteers
- 191 people
- Sponsor
- Ya-Wei Xu
Left Ventricular Hypertrophy
Belgian Screening Project for the Detection of Anderson-Fabry Disease in Hypertrophic Cardiomyopathy
The purpose of this study is to determine the prevalence of Fabry mutations in patients with left ventricular hypertrophy (moderate to severe), as measured by echocardiography.This study is a screening study
- Trial name
- NCT01198899
- Testing
- blood sampling
- Where
- 9 sites in Belgium
- Volunteers
- 540 people
- Sponsor
- University Hospital, Ghent
Cardiac Amyloidosis, Amyloidosis in Transthyretin (TTR)
Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy
Cardiac amyloidosis are related to the accumulation of fibrillar proteins in the extracellular leading to disruption of the cardiac tissue architecture.
- Conditions
- Cardiac Amyloidosis, Amyloidosis in Transthyretin (TTR), Hypertrophic Cardiomyopathy (HCM)
- Trial name
- Amylo (NCT01623245)
- Where
- France
- Volunteers
- 294 people
- Sponsor
- Thibaud Damy
Cardiomegaly, Noonan Syndrome
MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies
The goal of this study is to evaluate the effectiveness of trametinib treatment in patients with Hyperthropic cardiomyopathy and a genetic mutation in the RAS/MAPK pathway.
- Trial name
- MEKinRAS (NCT06555237)
- Testing
- Trametinib tablet, Standard therapy
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Medical University of Warsaw
Hypertrophic Cardiomyopathy
A Biomarker and MRI Study on Troponin Release After Exercise in Hypertrophic Cardiomyopathy
Study population: 1) mutation carriers without the hypertrophic phenotype (pre-clinical Hypertrophic Cardiomyopathy (HCM)) and in 2) patients with clinically overt HCM (clinical HCM).
- Trial name
- BE STRONG HCM (NCT01559714)
- Where
- Netherlands
- Volunteers
- 81 people
- Sponsor
- Heartcenter, University Medical Center St. Radboud
Hypertrophic Cardiomyopathy, Depression
Efficacy of Psychotherapy for Improving Quality of Life in Patients With Hypertrophic Cardiomyopathy and Depression
A Study to evaluate the efficacy of psychotherapy for easing the cardiac symptoms and improving and quality of life in patients with hypertrophic cardiomyopathy accompanied with depression
- Conditions
- Hypertrophic Cardiomyopathy, Depression, Anxiety, Psychotherapy
- Trial name
- NCT03706001
- Testing
- Psychotherapy
- Volunteers
- 100 people
- Sponsor
- Xijing Hospital
HCM - Hypertrophic Cardiomyopathy
Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients Using Hybrid Digital Twin Solutions
The goal of SMASH-HCM is to develop a digital twin or virtual model of the heart and vascular system with sympathetic nerve control that integrates multi-scale and multi-organ spatiotemporal biophysical data from a multitude of…
- Trial name
- SMASH-HCM (NCT07131371)
- Where
- Finland
- Volunteers
- 2,500 people
- Sponsor
- Tampere University
Cardiomyopathy, Hypertrophic, Muscular Dystrophy, Oculopharyngeal
Study of Muscle Abnormalities in Patients With Specific Genetic Mutations
Hypertrophic cardiomyopathy (HCM) is a genetically inherited disease affecting the heart. It causes thickening of heart muscle, especially the chamber responsible for pumping blood out of the heart, the left ventricle.
- Trial name
- NCT00001871
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Anesthesia, Transapical Beating-heart Septal Myectomy
Anesthetic Management for TA-BSM in HOCM
To retrospectively analyze the preoperative, intraoperative and postoperative anesthesia management of patients with hypertrophic cardiomyopathy undergoing TA-BSM in the investigators' hospital, and to provide clinical basis for…
- Conditions
- Anesthesia, Transapical Beating-heart Septal Myectomy, Hypertrophic Cardiomyopathy
- Trial name
- NCT06397092
- Testing
- transapical beating-heart septal myectomy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tongji Hospital
Hypertrophic Cardiomyopathy, Sudden Cardiac Death
PRecIsion Medicine in CardiomyopathY
This is a retrospective cohort study of pediatric hypertrophic cardiomyopathy (HCM) patients using chart and registry review methodology.
- Trial name
- PRIMaCY (NCT04036799)
- Volunteers
- 572 people
- Sponsor
- The Hospital for Sick Children
Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy Federated Learning Implementation Platform
HCM FLIP study is a two-phase protocol focusing on the detection of Hypertrophic Cardiomyopathy using Electrocardiograms and Echocardiograms through Federated Learning.
- Trial name
- HCM FLIP (NCT06461468)
- Where
- 6 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- American Heart Association
Hypertrophic Cardiomyopathy
Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER
This is a multicenter open-label study of the administration of mavacamten in participants with symptomatic obstructive HCM (oHCM) who previously participated in study MYK-461-004 (PIONEER-HCM).
- Trial name
- PIONEER-OLE (NCT03496168)
- Testing
- mavacamten
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Bristol-Myers Squibb
Hypertrophic Cardiomyopathy (HCM)
Role of Cardiovascular Imaging in the Early Diagnosis of Hypertrophic Cardiomyopathy in Women
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disorder worldwide with a prevalence of 1:500 in the general population.
- Trial name
- IMAGE-HCM (NCT06882668)
- Where
- Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Hypertrophic Obstructive Cardiomyopathy \(HOCM\), Left Ventricular Outflow Tract Obstruction
Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial
Hypertrophic obstructive cardiomyopathy (HOCM) is a heritable heart condition that leads to the thickening of the heart muscle and causes obstruction of blood flow, impeding it's ejection from the heart (LVOT obstruction).
- Conditions
- Hypertrophic Obstructive Cardiomyopathy \(HOCM\), Left Ventricular Outflow Tract Obstruction, Myocardial Ischaemia
- Trial name
- PEACH (NCT07120776)
- Testing
- Camzyos (Mavacamten)
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- University of Manchester
Non-obstructive Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy
Effects of Continous Positive Airway Pressure (CPAP) in Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease, is a cause of disability including heart failure, atrial fibrillation, and sudden death, with an annual mortality varying from 1% to 6%.
- Trial name
- CPAPandHCM (NCT01631006)
- Testing
- CPAP
- Where
- Brazil
- Volunteers
- 26 people
- Sponsor
- University of Sao Paulo
Hypertrophic Cardiomyopathy
Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy (HCM) is a relatively common inherited heart muscle disease. Many patients experience symptoms of breathlessness, fatigue and chest pain.
- Trial name
- METAL-HCM (NCT00500552)
- Where
- 3 sites in United Kingdom
- Volunteers
- 44 people
- Sponsor
- University Hospital Birmingham
Symptomatic Obstructive Hypertrophic Cardiomyopathy, Healthy Subjects
A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects
The purposes of this study are to: 1. Learn about the safety of CK-3773274 after a single dose and multiple doses in healthy subjects. 2. Learn how healthy subjects tolerate CK-3773274 after a single dose and multiple doses. 3.
- Trial name
- NCT03767855
- Testing
- CK-3773274 - Granules in Capsule, CK-3773274 - Tablets
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Cytokinetics
Hypertrophic Cardiomyopathy
Taiwan Registry of Hypertrophic Cardiomyopathy (THIC) Research Synopsis
Hypertrophic cardiomyopathy (HCM) is hallmarked by the presence of left ventricular hypertrophy (LVH) and may present various symptoms including arrhythmia and heart failure.
- Trial name
- NCT06381778
- Where
- Taiwan
- Volunteers
- 2,600 people
- Sponsor
- Far Eastern Memorial Hospital
Hypertrophic Cardiomyopathy, Hypertrophic Obstructive Cardiomyopathy
Comparison of Squat-to-Stand Maneuver With Amyl Nitrite, Valsalva, and Exercise Stress Echocardiography in Inducing Latent Left Ventricular Outflow Obstruction in Hypertrophic Cardiomyopathy
The purpose of this study is to assess the effectiveness of squat-to-stand maneuver in eliciting left ventricular outflow gradients in patients with Hypertrophic Cardiomyopathy (HCM) compared to Valsalva, amyl nitrite inhalation…
- Conditions
- Hypertrophic Cardiomyopathy, Hypertrophic Obstructive Cardiomyopathy, Cardiomyopathy, Hypertrophic
- Trial name
- NCT04905173
- Testing
- Squat-to-stand maneuver, Amyl nitrite inhalation, Valsalva
- Sponsor
- Mayo Clinic